# EDGAR Filing Document

**Accession Number:** 0000898860
**File Stem:** 0001493152-25-020250
**Filing Date:** 2025-10
**Character Count:** 12873
**Document Hash:** 6d0d6713f39f351114c8fe101d3dc920
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-020250.hdr.sgml**: 20251030

**ACCESSION NUMBER**: 0001493152-25-020250

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251030

**DATE AS OF CHANGE**: 20251030

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cocrystal Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001412486
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 352528215
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87608
- **FILM NUMBER:** 251436574

**BUSINESS ADDRESS:**
- **STREET 1:** 19805 N. CREEK PARKWAY
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98011
- **BUSINESS PHONE:** (786) 459-1831

**MAIL ADDRESS:**
- **STREET 1:** 19805 N. CREEK PARKWAY
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIOZONE PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20110304

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** International Surf Resorts, Inc.
- **DATE OF NAME CHANGE:** 20070917
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FROST PHILLIP MD ET AL
- **CENTRAL INDEX KEY:** 0000898860

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 4400 BISCAYNE BLVD
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33137-3227

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 7)**

**Cocrystal Pharma, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**19188J409**

*(CUSIP Number)*

**Phillip Frost, M.D.**<br>Frost Gamma Investments Trust<br>4400 Biscayne Boulevard<br>Miami FL 33137<br>(305) 575-6015

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/28/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **19188J409** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Phillip Frost, M.D.** | Name of reporting person<br>**Phillip Frost, M.D.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1694794.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1694794.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2462012.00** | Aggregate amount beneficially owned by each reporting person<br>**2462012.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.8%** | Percent of class represented by amount in Row (11)<br>**17.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) The amounts provided in Item 7 and 9 include (i) 15,243 shares of the Issuer's common stock and (ii) 1,679,551 shares of the Issuer's common stock, which is controlled by Dr. Frost as sole trustee. Does not include options to acquire 47,792 shares of common stock and warrants to acquire 719,426 shares of common stock, both of which are exercisable within 60 days.

(2) The amount provided in Item 11 includes (i) 15,243 shares of common stock owned, (ii) 1,679,551 shares of the Issuer's common stock held by Frost Gamma Investments Trust, which is controlled by Dr. Frost as sole trustee; (iii) options to acquire 47,792 shares of common stock, which are exercisable within 60 days and (iv) 719,426 warrants to acquire shares of common stock, which is controlled by Dr. Frost as sole trustee and are exercisable within 60 days.

(3) The percentage provided in Item 13 is calculated based on (i) 13,039,350 shares of common stock outstanding as of September 18, 2025 and (ii) 47,792 shares of common stock issuable upon exercise of options and 719,426 shares of common stock issuable upon exercise of warrants within 60 days. The percentage reflected in the table above is rounded to the nearest tenth (one place after the decimal point) in accordance with the instructions to Schedule 13D.

| **CUSIP No.** | **19188J409** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Frost Gamma Investments Trust** | Name of reporting person<br>**Frost Gamma Investments Trust** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**FLORIDA** | Citizenship or place of organization<br>**FLORIDA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1679551.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1679551.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2398977.00** | Aggregate amount beneficially owned by each reporting person<br>**2398977.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**17.4%** | Percent of class represented by amount in Row (11)<br>**17.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1) The amounts provided in Item 7 and 9 include 1,679,551 shares of the Issuer's common stock, which is controlled by Dr. Frost as sole trustee. Does not include warrants to acquire 719,426 shares of common stock, which are exercisable within 60 days.

(2) The amount provided in Item 11 includes (i) 1,679,551 shares of the Issuer's common stock and (ii) 719,426 warrants to acquire shares of the Issuer's common stock, which are exercisable within 60 days. The securities are controlled by Dr. Frost as sole trustee.

(3) The percentage provided in Item 13 is calculated based upon 13,039,350 shares of common stock outstanding as of September 18, 2025 and 719,426 shares of common stock issuable upon exercise of warrants within 60 days. The percentage reflected in the table above is rounded to the nearest tenth (one place after the decimal point) in accordance with the instructions to Schedule 13D.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
Cocrystal Pharma, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
19805 N. CREEK PARKWAY, BOTHELL, WA, 98011

This Amendment No. 7 on Schedule 13D/A (this "Amendment") is being filed with the Securities and Exchange Commission (the "SEC") on behalf of the Reporting Persons (as defined below) and relates to the common stock, par value $0.001 per share, of Cocrystal Pharma, Inc. (the "Issuer"). This Amendment is being filed as a result of a change in the Reporting Person's beneficial ownership of the common stock, and in the total number of shares of the Issuer's issued and outstanding common stock and, where so stated, amends and supplements Amendment No. 6 to the Schedule 13D and all previous filings on Schedule 13D.

**Item 4. Purpose of Transaction**

The Reporting Persons acquired the shares of common stock for investment purposes. On October 28, 2025, the Reporting Person acquired 359,713 shares of the Issuer's common stock and 719,426 warrants to purchase shares of the Issuer's common stock in connection with an offering.

These securities are held by FGIT, of which Phillip Frost, MD is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of FGIT. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole shareholder of Frost-Nevada Corporation. Dr. Frost disclaims beneficial ownership of the securities held by FGIT except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The beneficial ownership percentages disclosed below are based on 13,039,350 shares of common stock outstanding as of September 18, 2025, 47,792 shares of common stock issuable upon exercise of options and 719,426 shares of common stock issuable upon exercise of warrants, both within 60 days.

Dr. Frost is the beneficial owner of 2,462,012 shares of common stock representing 17.8% of the shares outstanding of the Issuer, including (i) 1,679,551 shares of common stock held by FGIT, (ii) 15,243 shares of the Issuer's common stock held by the Reporting Person, (iii) 47,792 shares of common stock issuable upon exercise of vested options and (iv) 719,426 shares of common stock issuable upon exercise of warrants. Dr. Frost is the trustee of FGIT. Frost Gamma Limited Partnership is the sole and exclusive beneficiary of FGIT. Dr. Frost is one of two limited partners of Frost Gamma Limited Partnership. Dr. Frost is the sole shareholder of Frost-Nevada Corporation, which is the sole shareholder of Frost Gamma, Inc., the general partner of Frost Gamma Limited Partnership. As a result of the foregoing, Dr. Frost may be deemed the beneficial owner of the shares of common stock held by FGIT. Dr. Frost disclaims beneficial ownership of the securities held by FGIT except to the extent of any pecuniary interest therein.

Dr. Frost has sole dispositive power with respect to 47,792 shares of common stock issuable upon exercise of vested options.

**(b)**
The Reporting Persons have voting and dispositive power over the Issuer's securities as described above in Item 5(a).

**(c)**
Except as described in this Schedule 13D under Item 3 above, the Reporting Persons did not engage in any transactions in shares of the Company's common stock during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Not applicable.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Phillip Frost, M.D.

**Signature:** /s/ Phillip Frost, M.D.

**Name/Title:** Phillip Frost, M.D.

**Date:** 10/30/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Frost Gamma Investments Trust

**Signature:** /s/ Phillip Frost, M.D.

**Name/Title:** Phillip Frost, M.D., Trustee

**Date:** 10/30/2025